The concern of generic competition has repeatedly loomed over copyright’s famous drug, PDE5 Inhibitor, triggering questions about the prospects of similar pharmaceutical stakes. While first times saw substantial profits, the patent lapse has created here the path for less expensive alternatives, possibly lowering earnings and presenting a real ri